全文获取类型
| 收费全文 | 1718675篇 |
| 免费 | 136138篇 |
| 国内免费 | 4095篇 |
专业分类
| 耳鼻咽喉 | 24259篇 |
| 儿科学 | 55016篇 |
| 妇产科学 | 49665篇 |
| 基础医学 | 249729篇 |
| 口腔科学 | 49822篇 |
| 临床医学 | 154102篇 |
| 内科学 | 328337篇 |
| 皮肤病学 | 37216篇 |
| 神经病学 | 138075篇 |
| 特种医学 | 67665篇 |
| 外国民族医学 | 462篇 |
| 外科学 | 262740篇 |
| 综合类 | 44856篇 |
| 现状与发展 | 2篇 |
| 一般理论 | 629篇 |
| 预防医学 | 135536篇 |
| 眼科学 | 40773篇 |
| 药学 | 126552篇 |
| 3篇 | |
| 中国医学 | 3360篇 |
| 肿瘤学 | 90109篇 |
出版年
| 2018年 | 16646篇 |
| 2016年 | 14868篇 |
| 2015年 | 17042篇 |
| 2014年 | 23706篇 |
| 2013年 | 36346篇 |
| 2012年 | 48251篇 |
| 2011年 | 51067篇 |
| 2010年 | 30291篇 |
| 2009年 | 28542篇 |
| 2008年 | 47940篇 |
| 2007年 | 51488篇 |
| 2006年 | 51740篇 |
| 2005年 | 50207篇 |
| 2004年 | 49021篇 |
| 2003年 | 47097篇 |
| 2002年 | 45593篇 |
| 2001年 | 75029篇 |
| 2000年 | 76691篇 |
| 1999年 | 64680篇 |
| 1998年 | 18930篇 |
| 1997年 | 17289篇 |
| 1996年 | 17139篇 |
| 1995年 | 16311篇 |
| 1994年 | 15480篇 |
| 1993年 | 14509篇 |
| 1992年 | 53574篇 |
| 1991年 | 52515篇 |
| 1990年 | 51611篇 |
| 1989年 | 49876篇 |
| 1988年 | 45990篇 |
| 1987年 | 45920篇 |
| 1986年 | 43147篇 |
| 1985年 | 41926篇 |
| 1984年 | 31933篇 |
| 1983年 | 27330篇 |
| 1982年 | 16758篇 |
| 1981年 | 15314篇 |
| 1979年 | 31060篇 |
| 1978年 | 22442篇 |
| 1977年 | 18935篇 |
| 1976年 | 17746篇 |
| 1975年 | 18884篇 |
| 1974年 | 23202篇 |
| 1973年 | 22352篇 |
| 1972年 | 20866篇 |
| 1971年 | 19402篇 |
| 1970年 | 18331篇 |
| 1969年 | 17464篇 |
| 1968年 | 15934篇 |
| 1967年 | 14488篇 |
排序方式： 共有10000条查询结果，搜索用时 15 毫秒
31.
Martin R. Späth Malte P. Bartram Nicolàs Palacio-Escat K. Johanna R. Hoyer Cedric Debes Fatih Demir Christina B. Schroeter Amrei M. Mandel Franziska Grundmann Giuliano Ciarimboli Andreas Beyer Jayachandran N. Kizhakkedathu Susanne Brodesser Heike Göbel Jan U. Becker Thomas Benzing Bernhard Schermer Martin Höhne Markus M. Rinschen 《Kidney international》2019,95(2):333-349
32.
Elizabeth D. Krebs Robert B. Hawkins J. Hunter Mehaffey Clifford E. Fonner Alan M. Speir Mohammed A. Quader Jeffrey B. Rich Leora T. Yarboro Nicholas R. Teman Gorav Ailawadi 《The Journal of thoracic and cardiovascular surgery》2019,157(4):1533-1542.e2
Objectives
Expedient extubation after cardiac surgery has been associated with improved outcomes, leading to postoperative extubation frequently during overnight hours. However, recent evidence in a mixed medical-surgical intensive care unit population demonstrated worse outcomes with overnight extubation. This study investigated the impact of overnight extubation in a statewide, multicenter Society of Thoracic Surgeons database.Methods
Records from 39,812 patients undergoing coronary artery bypass grafting or valve operations (2008-2016) and extubated within 24 hours were stratified according to extubation time between 06:00 and 18:00 (day) or between 18:00 and 6:00 (overnight). Outcomes including reintubation, mortality, and composite morbidity-mortality were evaluated using hierarchical regression models adjusted for Society of Thoracic Surgeons predictive risk scores. To further analyze extubation during the night, a subanalysis stratified patients into 3 groups: 06:00 to 18:00, 18:00 to 24:00, and 24:00 to 06:00.Results
A total of 20,758 patients were extubated overnight (52.1%) and were slightly older (median age 66 vs 65 years, P < .001) with a longer duration of ventilation (4 vs 7 hours, P < .001). Day and overnight extubation were associated with equivalent operative mortality (1.7% vs 1.7%, P = .880), reintubation (3.7% vs 3.4%, P = .141), and composite morbidity-mortality (8.2% vs 8.0%, P = .314). After risk adjustment, overnight extubation was not associated with any difference in reintubation, mortality, or composite morbidity-mortality. On subanalysis, those extubated between 24:00 and 06:00 exhibited increased composite morbidity-mortality (odds ratio, 1.18; P = .001) but no difference in reintubation or mortality.Conclusions
Extubation overnight was not associated with increased mortality or reintubation. These results suggest that in the appropriate clinical setting, it is safe to routinely extubate cardiac surgery patients overnight. 相似文献33.
34.
Whitney S. Brandt Wanpu Yan Jian Zhou Kay See Tan Joseph Montecalvo Bernard J. Park Prasad S. Adusumilli James Huang Matthew J. Bott Valerie W. Rusch Daniela Molena William D. Travis Mark G. Kris Jamie E. Chaft David R. Jones 《The Journal of thoracic and cardiovascular surgery》2019,157(2):743-753.e3
Objective
Comparative survival between neoadjuvant chemotherapy and adjuvant chemotherapy for patients with cT2-4N0-1M0 non–small cell lung cancer has not been extensively studied.Methods
Patients with cT2-4N0-1M0 non–small cell lung cancer who received platinum-based chemotherapy were retrospectively identified. Exclusion criteria included stage IV disease, induction radiotherapy, and targeted therapy. The primary end point was disease-free survival. Secondary end points were overall survival, chemotherapy tolerance, and ability of Response Evaluation Criteria In Solid Tumors response to predict survival. Survival was estimated using the Kaplan–Meier method, compared using the log-rank test and Cox proportional hazards models, and stratified using matched pairs after propensity score matching.Results
In total, 330 patients met the inclusion criteria (n = 92/group after propensity-score matching; median follow-up, 42 months). Five-year disease-free survival was 49% (95% confidence interval, 39-61) for neoadjuvant chemotherapy versus 48% (95% confidence interval, 38-61) for adjuvant chemotherapy (P = .70). On multivariable analysis, disease-free survival was not associated with neoadjuvant chemotherapy or adjuvant chemotherapy (hazard ratio, 1.1; 95% confidence interval, 0.64-1.90; P = .737), nor was overall survival (hazard ratio, 1.21; 95% confidence interval, 0.63-2.30; P = .572). The neoadjuvant chemotherapy group was more likely to receive full doses and cycles of chemotherapy (P = .014/0.005) and had fewer grade 3 or greater toxicities (P = .001). Response Evaluation Criteria In Solid Tumors response to neoadjuvant chemotherapy was associated with disease-free survival (P = .035); 15% of patients receiving neoadjuvant chemotherapy (14/92) had a major pathologic response.Conclusions
Timing of chemotherapy, before or after surgery, is not associated with an improvement in overall or disease-free survival among patients with cT2-4N0-1M0 non–small cell lung cancer who undergo complete surgical resection. 相似文献35.
36.
B Maybury A Powell-Chandler N Kumar 《Annals of the Royal College of Surgeons of England》2015,97(3):e37-e38
We report two British cases of liver abscess, due to Klebsiella pneumoniae and associated with synchronous infection elsewhere, which required liver resection for definitive treatment. They illustrate the geographic spread of aggressive K pneumoniae liver infection and demonstrate the importance of early aggressive treatment. 相似文献
37.
Alina Goldenberg B.A. Catalina Matiz M.D. Lawrence F. Eichenfield M.D. 《Pediatric dermatology》2015,32(4):e191-e192
Henna, derived from a combination of natural leaves and coloring additives, is a common decorative dye traditionally used in many Islamic religious celebrations. Para‐phenylenediamine (PPD), a major component of black henna tattoo, is a strong sensitizer and common allergen. We report a case of severe connubial allergic contact dermatitis after black henna heterotransfer in a girl. 相似文献
38.
39.
Autoimmune comorbid diseases associated with lichen planus: a nationwide case–control study 
下载免费PDF全文
下载免费PDF全文 40.
M.T. Leccia N. Auffret F. Poli J.‐P. Claudel S. Corvec B. Dreno 《Journal of the European Academy of Dermatology and Venereology》2015,29(8):1485-1492
Acne vulgaris (acne) is a chronic inflammatory disease of the sebaceous gland, characterized by follicular hyperkeratinization, excessive colonization by Propionibacterium acnes (P. acnes) as well as immune reactions and inflammation. Despite an armamentarium of topical treatments available including benzoyl peroxide, retinoids and azelaic acid, topical antibiotics in monotherapies, especially erythromycin and clindamycin, are still used in Europe to treat acne. This intensive use led to antimicrobial‐resistant P. acnes and staphylococci strains becoming one of the main health issues worldwide. This is an update on the current topical acne treatments available in Europe, their mechanism of action, their potential to induce antimicrobial resistance and their clinical efficacy and safety. 相似文献